Genfit S.A (GNFT) | Financial Analysis & Statements
Genfit S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2023Income Metrics
Revenue
14.3M
Balance Sheet Metrics
Total Assets
159.0M
Total Liabilities
181.6M
Shareholders Equity
-22.5M
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2023
Annual Income Flow
2025
Genfit S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 65.4M | 67.0M | 28.6M | 20.2M | 80.1M |
| Cost of Goods Sold | 302.0K | 300.0K | 341.0K | 251.0K | 162.0K |
| Gross Profit | 65.1M | 66.7M | 28.2M | 19.9M | 79.9M |
| Gross Margin % | 99.5% | 99.6% | 98.8% | 98.8% | 99.8% |
| Operating Expenses | |||||
| Research & Development | 103.5M | 47.4M | 46.7M | 35.9M | 35.3M |
| Selling, General & Administrative | - | 8.7M | 8.0M | 7.3M | 8.2M |
| Other Operating Expenses | 11.1M | 11.0M | 9.9M | 3.9M | 3.6M |
| Total Operating Expenses | 114.5M | 67.0M | 64.7M | 47.1M | 47.0M |
| Operating Income | -53.6M | 3.2M | -27.2M | -27.3M | 32.4M |
| Operating Margin % | -81.9% | 4.8% | -95.1% | -135.3% | 40.4% |
| Non-Operating Items | |||||
| Interest Income | 1.5M | 1.8M | 1.7M | 137.0K | 274.0K |
| Interest Expense | 1.2M | 4.7M | 4.6M | 4.4M | 5.0M |
| Other Non-Operating Income | - | 791.0K | 72.0K | 7.2M | 6.2M |
| Pre-tax Income | -86.5M | 1.8M | -28.5M | -23.8M | 69.5M |
| Income Tax | -531.0K | 340.0K | 380.0K | -116.0K | 2.2M |
| Effective Tax Rate % | 0.0% | 18.4% | 0.0% | 0.0% | 3.2% |
| Net Income | -86.0M | 1.5M | -28.9M | -23.7M | 67.3M |
| Net Margin % | -131.4% | 2.2% | -101.2% | -117.4% | 84.0% |
| Key Metrics | |||||
| EBITDA | -83.4M | 8.3M | -22.8M | -24.8M | 71.0M |
| EPS (Basic) | - | €0.03 | €-0.58 | €-0.48 | €1.51 |
| EPS (Diluted) | - | €0.03 | €-0.58 | €-0.48 | €1.23 |
| Basic Shares Outstanding | - | 49754474 | 49700223 | 49414583 | 44739756 |
| Diluted Shares Outstanding | - | 49754474 | 49700223 | 49414583 | 44739756 |
Income Statement Trend
Genfit S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 101.1M | 81.8M | 77.8M | 136.0M | 258.8M |
| Short-term Investments | - | - | 0 | 4.6M | 0 |
| Accounts Receivable | 31.5M | 2.1M | 18.5M | 3.2M | 7.2M |
| Inventory | 4.0K | 4.0K | 4.0K | 4.0K | 4.0K |
| Other Current Assets | - | 1.0K | 1.0K | 1.0K | - |
| Total Current Assets | 144.3M | 92.8M | 113.1M | 158.5M | 268.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.8M | 5.2M | 5.3M | 6.5M | 6.3M |
| Goodwill | 4.2M | 48.0M | 48.8M | 44.0M | 174.0K |
| Intangible Assets | 4.2M | 48.0M | 48.8M | 44.0M | 174.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.0K | 353.0K | 530.0K | 0 | 517.0K |
| Total Non-Current Assets | 14.8M | 58.7M | 60.8M | 57.1M | 13.6M |
| Total Assets | 159.0M | 151.4M | 173.9M | 215.5M | 281.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.9M | 13.4M | 10.4M | 8.6M | 12.3M |
| Short-term Debt | 42.9M | 56.6M | 7.9M | 5.1M | 2.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | -1.0K | -1.0K | - | - | - |
| Total Current Liabilities | 72.3M | 75.2M | 38.5M | 39.4M | 62.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 107.8M | 5.6M | 62.3M | 70.2M | 72.0M |
| Deferred Tax Liabilities | 0 | 145.0K | 455.0K | 510.0K | 602.0K |
| Other Non-Current Liabilities | 1.0K | - | - | 1.0K | 2.0K |
| Total Non-Current Liabilities | 109.3M | 7.0M | 67.4M | 81.6M | 99.8M |
| Total Liabilities | 181.6M | 82.2M | 105.9M | 121.0M | 162.6M |
| Equity | |||||
| Common Stock | 12.5M | 12.5M | 12.5M | 12.5M | 12.5M |
| Retained Earnings | -475.8M | -390.6M | -390.8M | -361.3M | -337.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -22.5M | 69.2M | 68.0M | 94.5M | 119.1M |
| Key Metrics | |||||
| Total Debt | 150.7M | 62.1M | 70.2M | 75.3M | 74.2M |
| Working Capital | 72.0M | 17.6M | 74.6M | 119.1M | 205.3M |
Balance Sheet Composition
Genfit S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -86.0M | 1.5M | -28.9M | -23.7M | 67.3M |
| Depreciation & Amortization | - | 1.7M | 1.7M | 1.8M | 2.7M |
| Stock-Based Compensation | 308.0K | 610.0K | 578.0K | 245.0K | 470.0K |
| Working Capital Changes | -32.7M | 8.4M | -27.8M | -54.8M | 59.7M |
| Operating Cash Flow | -88.8M | 15.5M | -54.5M | -72.3M | 101.5M |
| Investing Activities | |||||
| Capital Expenditures | -1.3M | -899.0K | -242.0K | 271.0K | -102.0K |
| Acquisitions | - | 0 | 0 | -41.5M | 0 |
| Investment Purchases | -250.0K | -140.0K | -12.0K | -5.0M | -3.1M |
| Investment Sales | 0 | 0 | 4.6M | 0 | 0 |
| Investing Cash Flow | -1.6M | -1.0M | 4.3M | -46.3M | -3.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | 0 | 0 |
| Debt Issuance | 130.0M | 0 | 89.0K | 0 | 15.3M |
| Debt Repayment | -63.1M | -9.2M | -3.6M | -1.7M | -50.3M |
| Financing Cash Flow | 53.5M | -9.5M | -4.0M | -3.8M | -8.9M |
| Free Cash Flow | -29.7M | 14.6M | -57.9M | -72.6M | 99.4M |
| Net Change in Cash | -36.8M | 5.0M | -54.2M | -122.4M | 89.3M |
Cash Flow Trend
Genfit S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
103.53
Forward P/E
-11.19
Price to Sales
6.28
PEG Ratio
-11.19
Profitability Ratios
Profit Margin
-131.38%
Operating Margin
-179.59%
Return on Equity
-368.27%
Return on Assets
-21.59%
Financial Health
Current Ratio
2.00
Debt to Equity
-6.69
Beta
1.14
Per Share Data
EPS (TTM)
€-1.72
Book Value per Share
€-0.45
Revenue per Share
€1.31
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GNFT | 410.7M | 103.53 | - | -368.27% | -131.38% | -6.69 |
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| Medincell S.A | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
Financial data is updated regularly. All figures are in the company's reporting currency.